Delivery Order SPE2DB22D2007-SPE2DB25FJ3PE
- Not listed
- The Defense Logistics Agency awarded a $13,630.99 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $44,046.64 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract, which is expected to be completed by August 12, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same...
- The Defense Logistics Agency awarded a delivery order valued at $33,274.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and does not include a set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication...
- The Defense Logistics Agency awarded a $40,179.46 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $26,836.77 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion targeted for July 25, 2025. This firm fixed-price contract represents a single delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was not set-aside and resulted from competitive procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $33,157.91. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 6, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic immunosuppressant medication used to treat various allergic and...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3PEDelivery Order
The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. Dupixent (dupilumab) is a biologic medication commonly prescribed for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, making this delivery order part of AmerisourceBergen's extensive portfolio of specialty pharmaceutical products supplied to the Defense Health Agency and other federal healthcare systems. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen has demonstrated consistent capability in fulfilling competitively awarded delivery orders across diverse therapeutic domains through its partnership with the Defense Logistics Agency's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $63.2k | 8/4/25 |